Search

Search Constraints

You searched for: Author/Creator Posner, J.

Search Results

4. An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. (November 2018)

6. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. Issue 2 (January 2015)